The PE Ratio as of October 2024 (TTM) for Pluri Inc. (PLUR) is -1.21

According to Pluri Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.21. This represents a change of -126.55% compared to the average of 4.56 of the last 4 quarters.

Pluri Inc. (PLUR) Historical PE Ratio (quarterly & annually)

How has PLUR PE Ratio performed in the past?

The mean historical PE Ratio of Pluri Inc. over the last ten years is -3.39. The current -1.21 PE Ratio has changed 3.47% with respect to the historical average. Over the past ten years (40 quarters), PLUR's PE Ratio was at its highest in in the September 2023 quarter at 22.22. The PE Ratio was at its lowest in in the March 2018 quarter at -24.62.

Pluri Inc. (PLUR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Pluri Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pluri Inc. (PLUR) Average PE Ratio

How has PLUR PE Ratio performed in the past?

The current PE Ratio of Pluri Inc. (PLUR) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Pluri Inc. (PLUR) PE Ratio vs. Peers

How is PLUR’s PE Ratio compared to its peers?

Pluri Inc.’s PE Ratio is greater than BioLineRx Ltd. (-1.22), greater than Purple Biotech Ltd. (-7.21), less than Aridis Pharmaceuticals, Inc. (0.00), greater than Enlivex Therapeutics Ltd. (-1.43), greater than Transgene SA (-6.46), greater than Eupraxia Pharmaceuticals Inc. (-4.58), greater than Champions Oncology, Inc. (-17.77), greater than MAIA Biotechnology, Inc. (-1.99), less than Lumos Pharma, Inc. (-0.86), less than Evogene Ltd. (-0.55), greater than Arcus Biosciences, Inc. (-6.67), greater than Fate Therapeutics, Inc. (-2.15), less than Surface Oncology, Inc. (-0.69), greater than Compugen Ltd. (-16.25), less than BiomX Inc. (-0.35), greater than MediWound Ltd. (-8.41), greater than Foghorn Therapeutics Inc. (-4.62), greater than Eliem Therapeutics, Inc. (-2.42), greater than Sutro Biopharma, Inc. (-2.42), greater than Dyadic International, Inc. (-4.28),

Build a custom stock screener for Pluri Inc. (PLUR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pluri Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pluri Inc. (PLUR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pluri Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.